Lilly to Acquire POINT Biopharma for $1.4 Billion in Bid to Expand Cancer Therapy Portfolio
- October 06, 2023
Eli Lilly and Company will buy POINT Biopharma Global, Inc., a radiopharmaceutical company that develops targeted cancer therapies, in a deal valued at roughly $1.4 billion, the companies announced October 3.
ARTICLE TAGS
You must be logged in to access this content.